Lexaria Bioscience (LEXX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Lexaria Bioscience has appointed esteemed Harvard Medical School Professor Dr. Michael Gibson as Chief Medical Advisor to enhance its innovative drug delivery platform, DehydraTECH, particularly for hypertension and GLP-1 applications. Dr. Gibson brings significant expertise in cardiovascular research and clinical trials, promising to advance Lexaria’s drug development and optimization efforts. His extensive background and leadership in influential healthcare research are expected to drive Lexaria’s growth and improve pharmacokinetic drug performance.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
